Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD19 CAR vector-transduced T cells pCAR-19B

A preparation of autologous T lymphocytes that have been genetically modified and transduced with a vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation (CD) 19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR vector-transduced T cells pCAR-19B specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-CD19 CAR T cells pCAR-19B pCAR-19B pCAR-19B cells

autologous anti-CD19 CAR vector-transduced T cells pCAR-19B

Search NCI's Drug Dictionary